NASDAQ$ABCL
AbCellera Biologics Inc. · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
AbCellera reported a decrease in revenue and a net loss for Q1 2023, while advancing partnered programs and molecules in the clinic.
AbCellera reported Q1 2023 financial results, with a total revenue of $12.2 million compared to $316.6 million in Q1 2022. The company generated a net loss of $40.1 million, or $(0.14) per share, compared to net earnings of $168.6 million, or $0.59 per share in Q1 2022. They reached a cumulative total of 177 programs under contract and maintained 101 partnered program starts. One additional molecule was advanced into the clinic, bringing the cumulative total to nine molecules.
- Total revenue was $12.2 million, a decrease from $316.6 million in Q1 2022.
- Net loss was $40.1 million, or $(0.14) per share, compared to net earnings of $168.6 million in Q1 2022.
- Reached a cumulative total of 177 programs under contract with 41 different partners.
- Advanced one additional molecule into the clinic, bringing the cumulative total to nine molecules.
Headline financials
Revenue & EPS history
AbCellera · Revenue · Quarterly
$12.2M
Revenue by segment
AbCellera · $10.6M total across 1 segment · Q1 2023
- Research Fees$10.6M+13.3%100.0%
Forward guidance
This press release contains forward-looking statements regarding AbCellera's ability to develop, commercialize and achieve market acceptance of its products and services, research and development efforts, business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
-0.4%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+0.2%
Avg return
30 days after
46%
11 / 24 earnings
Positive
+17.1%
Q2 2021
Best reaction
-13.9%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.2% | -21.8% | -2.9% | |
| Q4 2025 | -1.5% | +18.6% | +1.6% | |
| Q3 2025 | -13.9% | -12.4% | -21.4% | |
| Q1 2025 | +1.0% | +2.0% | +21.4% | |
| Q4 2024 | -11.3% | -18.2% | -20.9% | |
| Q3 2024 | -0.4% | -1.1% | +6.2% | |
| Q2 2024 | -4.7% | -2.9% | -12.0% | |
| Q1 2024 | -6.6% | -6.8% | -8.0% | |
| Q4 2023 | -9.9% | -8.8% | -11.8% | |
| Q3 2023 | +14.1% | +6.8% | +17.2% | |
| Q2 2023 | -13.0% | -15.1% | -19.5% | |
| Q1 2023 | -9.1% | -14.1% | +3.0% | |
| Q4 2022 | -8.3% | -12.7% | -23.8% | |
| Q3 2022 | -1.7% | +13.1% | -7.2% | |
| Q2 2022 | +13.4% | +16.3% | -3.9% | |
| Q1 2022 | -12.0% | +11.2% | +29.1% | |
| Q4 2019 | +8.1% | +9.4% | +15.5% | |
| Q4 2021 | +8.1% | +9.4% | +15.5% | |
| Q3 2020 | -7.8% | -2.0% | -5.1% | |
| Q2 2018 | +16.3% | +10.3% | +25.0% | |
| Q2 2021 | +17.1% | +8.6% | +24.3% | |
| Q1 2018 | +0.1% | -5.2% | -24.1% | |
| Q1 2021 | +3.4% | +7.4% | -15.7% | |
| Q4 2018 | +7.8% | +24.1% | +21.3% | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro